https://ir.rezolutebio.com/news/rss en-us https://d1io3yog0oux5.cloudfront.net/_ccfa9d9a38d9c21c9cf5ba58fc58a234/rezolutebio/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society Wed, 17 Jun 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society https://ir.rezolutebio.com/news/detail/379/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-of-the-endocrine-society Thu, 04 Jun 26 07:30:00 -0400 https://ir.rezolutebio.com/news/detail/379/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-of-the-endocrine-society https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism Tue, 02 Jun 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism https://ir.rezolutebio.com/news/detail/377/rezolute-reports-third-quarter-fiscal-2026-financial-results-and-provides-business-update Tue, 12 May 26 16:05:00 -0400 https://ir.rezolutebio.com/news/detail/377/rezolute-reports-third-quarter-fiscal-2026-financial-results-and-provides-business-update https://ir.rezolutebio.com/news/detail/376/rezolute-to-participate-in-upcoming-investor-conferences Mon, 11 May 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/376/rezolute-to-participate-in-upcoming-investor-conferences https://ir.rezolutebio.com/news/detail/375/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting Fri, 01 May 26 12:15:00 -0400 https://ir.rezolutebio.com/news/detail/375/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting https://ir.rezolutebio.com/news/detail/374/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting Tue, 21 Apr 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/374/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting Tue, 24 Mar 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference Wed, 04 Mar 26 07:00:00 -0500 https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update Thu, 12 Feb 26 16:05:00 -0500 https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update